VIA
QNTM

Vident Investment Advisory’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Vident Investment Advisory’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-649
Closed -$67K – 1248
2021
Q3 		$67K Buy
+649
New +$69.3K ﹤0.01% 1143

Other funds holding QNTM

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RM
Resource Management Metairie, Louisiana $970M AUM 28.05% 1-Year Est. Return

Vident Investment Advisory's QNTM Position: Q4 2021 in Review

Vident Investment Advisory sold out of Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q4 2021, closing a stake of 649 shares — an estimated $67K sold.

Vident Investment Advisory first reported a position in QNTM in Q3 2021 and held it in 1 quarter. The position peaked at $67K in Q3 2021. 20 funds tracked by Wall St. Rank hold QNTM as of Q4 2021.

  • Vident Investment Advisory reported no remaining Quantum Biopharma Class B Subordinate Voting Shares position as of Q4 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 649 Quantum Biopharma Class B Subordinate Voting Shares shares in Q4 2021, an estimated $67K.
  • Vident Investment Advisory first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q3 2021 and held it in 1 quarter.
  • Vident Investment Advisory's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $67K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q4 2021.

Based on Vident Investment Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.